Proteasome Inhibition in the Treatment of Cancer

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Cell Cycle

• Publication date

  2005-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4161/cc.4.2.1414PMID 15655370
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 1 VEGF INDUCES MCL-1 UPREGULATION AND PROTECTS MULTIPLE MYELOMA CELLS AGAINST APOPTOSIS

  2004cited by this paper
• Phase (ph) 2 study of bortezomib ± docetaxel in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC): Preliminary results

  2004cited by this paper
• Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas

  2004cited by this paper
• Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.

  2004cited by this paper
• Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro

  2004cited by this paper
• Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line

  2004cited by this paper
• Recycling the cell cycle: cyclins revisited.

  2004cited by this paper
• Proteasome inhibitor PS‐341 down‐regulates prostate‐specific antigen (PSA) and induces growth arrest and apoptosis of androgen‐dependent human prostate cancer LNCaP cells

  2004cited by this paper
• Bortezomib ± irinotecan in relapsed/refractory colorectal cancer (CRC): Interim analysis results from phase (ph) 2b study.

  2004cited by this paper
• Synergistic Induction of Oxidative Injury and Apoptosis in Human Multiple Myeloma Cells by the Proteasome Inhibitor Bortezomib and Histone Deacetylase Inhibitors

  2004cited by this paper
• Proteasome inhibitor PS‐341 induces growth arrest and apoptosis of non‐small cell lung cancer cells via the JNK/c‐Jun/AP‐1 signaling

  2004cited by this paper
• Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.

  2004cited by this paper
• A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

  2004cited by this paper
• The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo.

  2004cited by this paper
• Phase II trial of bortezomib for patients with advanced renal cell carcinoma.

  2004cited by this paper
• Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias

  2004cited by this paper
• Recycling the Cell Cycle Cyclins Revisited

  2004cited by this paper
• Marked clinical activity of the novel proteasome inhibitor bortezomib in patients with relapsed follicular (RL) and mantle cell lymphoma (MCL).

  2004cited by this paper
• Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts.

  2003cited by this paper
• Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis.

  2003cited by this paper
• A phase 2 study of bortezomib in relapsed, refractory myeloma.

  2003cited by this paper
• Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

  2003cited by this paper
• The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.

  2003cited by this paper
• Potential for proteasome inhibition in the treatment of cancer.

  2003cited by this paper
• Inhibiting the p53–MDM2 interaction: an important target for cancer therapy

  2003cited by this paper
• The Caspase-like Sites of Proteasomes, Their Substrate Specificity, New Inhibitors and Substrates, and Allosteric Interactions with the Trypsin-like Sites*

  2003cited by this paper
• Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

  2003cited by this paper
• The proteasome: structure, function, and role in the cell.

  2003cited by this paper
• Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.

  2003cited by this paper
• Reactive Oxygen Species Generation and Mitochondrial Dysfunction in the Apoptotic Response to Bortezomib, a Novel Proteasome Inhibitor, in Human H460 Non-small Cell Lung Cancer Cells*

  2003cited by this paper
• The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.

  2003cited by this paper
• The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction.

  2002cited by this paper
• A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.

  2002cited by this paper
• Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.

  2002cited by this paper
• Molecular sequelae of proteasome inhibition in human multiple myeloma cells

  2002cited by this paper
• Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.

  2002cited by this paper
• NF-kappa B as a therapeutic target in multiple myeloma.

  2002cited by this paper
• Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.

  2001cited by this paper
• Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.

  2001cited by this paper
• The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

  2001cited by this paper
• Proteasome inhibitors: from research tools to drug candidates.

  2001cited by this paper
• Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.

  2001cited by this paper
• 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer

  2001cited by this paper
• Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.

  2001cited by this paper
• Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB

  2001cited by this paper
• Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome.

  2001cited by this paper
• Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress.

  2000cited by this paper
• The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L).

  2000cited by this paper
• Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes.

  2000cited by this paper
• Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341.

  2000cited by this paper
• Human THP-1 monocytic leukemic cells induced to undergo monocytic differentiation by bryostatin 1 are refractory to proteasome inhibitor-induced apoptosis.

  2000cited by this paper
• Catalytic activities of the 20 S proteasome, a multicatalytic proteinase complex.

  2000cited by this paper
• The Proteasome, a Novel Protease Regulated by Multiple Mechanisms*

  1999cited by this paper
• NF-κB Induces Expression of the Bcl-2 Homologue A1/Bfl-1 To Preferentially Suppress Chemotherapy-Induced Apoptosis

  1999cited by this paper
• Chaperone rings in protein folding and degradation.

  1999cited by this paper
• The base of the proteasome regulatory particle exhibits chaperone-like activity

  1999cited by this paper
• Proteasome inhibitors: a novel class of potent and effective antitumor agents.

  1999cited by this paper
• A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and eIF3.

  1998cited by this paper
• Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor.

  1998cited by this paper
• NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation.

  1998cited by this paper
• CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION

  1998cited by this paper
• Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts

  1998cited by this paper
• The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis.

  1998cited by this paper
• Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally.

  1998cited by this paper
• Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1.

  1998cited by this paper
• Contribution of Proteasomal β-Subunits to the Cleavage of Peptide Substrates Analyzed with Yeast Mutants*

  1998cited by this paper
• Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53

  1997cited by this paper
• Structure of 20S proteasome from yeast at 2.4Å resolution

  1997cited by this paper
• Regulation of p53 stability by Mdm2

  1997cited by this paper
• Mdm2 promotes the rapid degradation of p53

  1997cited by this paper
• Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway.

  1997cited by this paper
• Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation.

  1996cited by this paper
• How Proteolysis Drives the Cell Cycle

  1996cited by this paper
• Proteasomes: destruction as a programme.

  1996cited by this paper
• E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway.

  1996cited by this paper
• Kinetic characterization of the chymotryptic activity of the 20S proteasome.

  1996cited by this paper
• In vivo ubiquitination and proteasome-mediated degradation of p53(1).

  1996cited by this paper
• Proteasome from Thermoplasma acidophilum: a threonine protease.

  1995cited by this paper
• The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression.

  1995cited by this paper
• Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution.

  1995cited by this paper
• The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B.

  1994cited by this paper
• Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway

  1994cited by this paper
• Adhesion molecules in tumor metastasis.

  1993cited by this paper
• Cyclin is degraded by the ubiquitin pathway

  1991cited by this paper
• Abnormally high expression of proteasomes in human leukemic cells.

  1990cited by this paper

• TRIP13 alters mitochondrial function and promotes bortezomib resistance in multiple myeloma

  2025cites this paper
• Translational Strategies to Target Metastatic Bone Disease

  2022cites this paper
• Proteasome Inhibitors and Their Potential Applicability in Osteosarcoma Treatment

  2022cites this paper
• Targeting HIF-1α by Natural and Synthetic Compounds: A Promising Approach for Anti-Cancer Therapeutics Development

  2022cites this paper
• Aging and Susceptibility to Pulmonary Disease.

  2022cites this paper
• The Role of HSPB8, a Component of the Chaperone-Assisted Selective Autophagy Machinery, in Cancer

  2021cites this paper
• CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model

  2021cites this paper
• Ruthenium Complexes: An Alternative to Platinum Drugs in Colorectal Cancer Treatment

  2021cites this paper
• Evaluation of a Generic Bortezomib Molecule in Newly Diagnosed Multiple Myeloma Patients

  2021cites this paper
• Interleukin-8-Induced Invasion Assay in Triple-Negative Breast Cancer Cells.

  2020cites this paper
• Identification of proteasome inhibitors using analysis of gene expression profiles.

  2020cites this paper
• Efficient brain targeting and therapeutic intracranial activity of bortezomib through intranasal co-delivery with NEO100 in rodent glioblastoma models.

  2020cites this paper
• Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists

  2019cites this paper
• Efficient brain targeting and therapeutic intracranial activity of bortezomib through intranasal co-delivery with NEO100 in rodent glioblastoma models

  2019cites this paper
• Proteasome inhibition induces IKK-dependent interleukin-8 expression in triple negative breast cancer cells: Opportunity for combination therapy

  2018cites this paper
• Raman spectroscopy differentiates between sensitive and resistant multiple myeloma cell lines.

  2017cites this paper
• A Second-Generation Proteasome Inhibitor and Doxorubicin Modulates IL-6, pSTAT-3 and NF-kB Activity in MDA-MB-231 Breast Cancer Cells.

  2017cites this paper
• Comprehensive review on cardio-oncology: Role of multimodality imaging

  2017cites this paper
• Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer.

  2017cites this paper
• Mechanisms promoting and inhibiting the process of proteasomal degradation of cells

  2016cites this paper
• Bortezomib in Anti-Cancer Activity: A Potential Drug

  2016cites this paper
• The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells

  2016cites this paper
• Anti-tumoral effect of desmethylclomipramine in lung cancer stem cells

  2015cites this paper
• ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy

  2015cites this paper
• Hallmarks of the ageing lung

  2015cites this paper
• Anticancer drug bortezomib increases interleukin-8 expression in human monocytes.

  2015cites this paper
• The Role of Cathelicidin LL-37 in Cancer Development

  2015cites this paper
• Particle-Rich Cytoplasmic Structure (PaCS): Identification, Natural History, Role in Cell Biology and Pathology

  2014cites this paper
• Polyubiquitinated proteins, proteasome, and glycogen characterize the particle-rich cytoplasmic structure (PaCS) of neoplastic and fetal cells

  2014cites this paper
• The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells

  2014cites this paper
• Quantitative analysis of bortezomib-induced IL-8 gene expression in ovarian cancer cells.

  2014cites this paper
• Chromatin immunoprecipitation analysis of bortezomib-mediated inhibition of NFκB recruitment to IL-1β and TNFα gene promoters in human macrophages.

  2014cites this paper
• The small heat shock protein B 8 ( HSPB 8 ) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells

  2014cites this paper
• High frequencies of response after limited primary therapy for multiple myeloma.

  2013cites this paper
• Proteasome Inhibition by Bortezomib Increases IL-8 Expression in Androgen-Independent Prostate Cancer Cells: The Role of IKKα

  2013cites this paper
• [Proteasome inhibition as a new strategy in cancer therapy and chemoprevention].

  2013cites this paper
• Proteasome inhibition as a new strategy in cancer therapy and chemoprevention

  2013cites this paper
• Effects of proteasome inhibitors on bone cancer.

  2013cites this paper
• Long-term Incubation with Proteasome Inhibitors (PIs) Induces IκBα Degradation via the Lysosomal Pathway in an IκB Kinase (IKK)-dependent and IKK-independent Manner*

  2013cites this paper
• Bortezomib influences the expression of malignant plasma cells membrane antigens.

  2013cites this paper
• Proteasome Inhibition Increases Recruitment of IκB Kinase β (IKKβ), S536P-p65, and Transcription Factor EGR1 to Interleukin-8 (IL-8) Promoter, Resulting in Increased IL-8 Production in Ovarian Cancer Cells*

  2013cites this paper
• This information is current as α Cells : The Role of IKK Androgen-Independent Prostate Cancer Increases IL-8 Expression in Proteasome Inhibition by Bortezomib

  2013cites this paper
• FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy.

  2013cites this paper
• Möglichkeiten der Überwindung von Chemoresistenz beim kindlichen Rhabdomyosarkom

  2013cites this paper
• Non-Hodgkin’s B-cell lymphoma: Advances in molecular strategies targeting drug resistance

  2013cites this paper
• The significance of ubiquitin proteasome pathway in cancer development.

  2013cites this paper
• Therapeutic Enhancement of ER Stress by Insulin-Like Growth Factor I Sensitizes Myeloma Cells to Proteasomal Inhibitors

  2013cites this paper
• New Proteasome Inhibitors in Myeloma

  2012cites this paper
• Discovery of green tea polyphenol-based proteasome inhibitors - A successful collaboration with Tak-Hang (Bill) Chan

  2012cites this paper
• Rescue of Murine F508del CFTR Activity in Native Intestine by Low Temperature and Proteasome Inhibitors

  2012cites this paper
• Regulation and function of nuclear IκBα in inflammation and cancer.

  2012cites this paper
• Apoptosis induction through proteasome inhibitory activity of cucurbitacin D in human T‐cell leukemia

  2011influential citation
• Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib

  2011cites this paper
• MG132 inhibition of proteasome blocks apoptosis induced by severe DNA damage.

  2011cites this paper
• Molekulare Therapie des Mantelzelllymphoms - In Vitro Wirksamkeit des Proteasom-Inhibitors Bortezomib in Mono- und Kombinationstherapie

  2010cites this paper
• PI3K/p110 (cid:1) is a novel therapeutic target in multiple myeloma

  2010cites this paper
• PI3K/p110{delta} is a novel therapeutic target in multiple myeloma.

  2010cites this paper
• Phosphorylated TP63 Induces Transcription of RPN13, Leading to NOS2 Protein Degradation*

  2010cites this paper
• PI 3 K / p 110 is a novel therapeutic target in multiple myeloma

  2010cites this paper
• Multiple lipoma with hyperlipidemia in a multiple myeloma patient treated with bortezomib/dexamethazone.

  2010cites this paper
• Novel organic proteasome inhibitors identified by virtual and in vitro screening.

  2010cites this paper
• Análise proteômica de carcinomas primários de mama

  2010cites this paper
• Inhibition of Deubiquitinase Activity and Ubiquitination of Jak2 Blocks Cytokine Signaling and Induces Tumor Cell Apoptosis

  2010cites this paper
• Proteasome inhibition: a new therapeutic strategy to cancer treatment.

  2010cites this paper
• Bortezomib-induced Apoptosis in the Treatment of Non-small Cell Lung Cancer

  2009cites this paper
• Aneuploidy: cancer's fatal flaw?

  2009cites this paper
• Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells

  2009cites this paper
• The vital link between the ubiquitin-proteasome pathway and DNA repair: impact on cancer therapy.

  2009cites this paper
• In vitro activity of bortezomib in cultures of patient tumour cells—potential utility in haematological malignancies

  2009cites this paper
• ORIGINAL ARTICLE Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells

  2009cites this paper
• Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12.

  2009cites this paper
• Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression.

  2009cites this paper
• Control of HIF-1A Expression by eIF2A Phosphorylation-Mediated Translational Repression

  2009cites this paper
• NF-kappaB as a prognostic marker and therapeutic target in chronic lymphocytic leukemia.

  2009cites this paper
• The 26S Proteasome as a Therapeutic Target in Cancer: Beyond Protease Inhibitors?

  2009cites this paper
• Guilt by association: PAX3-FOXO1 regulates gene expression through selective destabilization of the EGR1 transcription factor

  2008cites this paper
• A therapeutic dose of doxorubicin activates ubiquitin-proteasome system-mediated proteolysis by acting on both the ubiquitination apparatus and proteasome.

  2008cites this paper
• Translational Nephrology Proteasome inhibition: a new therapeutic option in lupus nephritis? ∗

  2008cites this paper
• Dynamic Effect of Bortezomib on Nuclear Factor- (cid:1) B Activity and Gene Expression in Tumor Cells □ S

  2008cites this paper
• Ubiquitin Proteasome System Stress Underlies Synergistic Killing of Ovarian Cancer Cells by Bortezomib and a Novel HDAC6 Inhibitor

  2008cites this paper
• Bortezomib-Resistant Nuclear Factor-κB Activity in Multiple Myeloma Cells

  2008cites this paper
• Proteasome inhibitor MG-132 lowers gastric adenocarcinoma TMK1 cell proliferation via bone morphogenetic protein signaling.

  2008cites this paper
• Why is CLL refractory to bortezomib?

  2008cites this paper
• Proteasome inhibition: a new therapeutic option in lupus nephritis?

  2008cites this paper
• Ubiquitin Proteasome System Stress Underlies Synergistic Killing of Ovarian Cancer Cells by Bortezomib and a Novel HDAC 6 Inhibitor

  2008cites this paper
• Bone morphogenetic protein signalling is required for the anti‐mitogenic effect of the proteasome inhibitor MG‐132 on colon cancer cells

  2008influential citation
• Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits

  2008cites this paper
• Inhibitors of the Ubiquitin-Proteasome System and the cell death machinery: How many pathways are activated?

  2008influential citation
• Proteasome inhibitor MG-132 modifies coxsackie and adenovirus receptor expression in colon cancer cell line lovo

  2008cites this paper
• Recent prognostic factors in diffuse large B-cell lymphoma indicate NF-κB pathway as a target for new therapeutic strategies

  2008cites this paper
• Translational Nephrology Proteasome inhibition: a new therapeutic option in lupus nephritis? ∗

  2008cites this paper
• Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib.

  2008cites this paper
• Dynamic Effect of Bortezomib on Nuclear Factor-κB Activity and Gene Expression in Tumor Cells

  2008cites this paper
• UvA-DARE ( Digital Academic Repository ) ' From the cradle to the grave ' : novel therapeutic approaches to attack the microenvironment in chronic lymphocytic leukemia

  2008cites this paper
• The B(OH)-NH Analog Is a Surrogate for the Amide Bond (CO-NH) in Peptides:  An ab Initio Study.

  2007cites this paper
• Ubiquitin Signaling and Cancer Pathogenesis

  2007cites this paper
• Hypoxia-inducible transcription factor-1 alpha determines sensitivity of endothelial cells to the proteosome inhibitor bortezomib.

  2007cites this paper
• Enhancement of chemotherapeutic efficacy by small molecule inhibition of NF-kappaB and checkpoint kinases.

  2007cites this paper
• Role of the ubiquitin system and tumor viruses in AIDS-related cancer

  2007cites this paper
• Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics.

  2007influential citation